chr3-143266832-G-T
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_173653.4(SLC9A9):c.1808C>A(p.Ala603Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000436 in 1,614,030 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_173653.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC9A9 | NM_173653.4 | c.1808C>A | p.Ala603Glu | missense_variant | 16/16 | ENST00000316549.11 | |
SLC9A9 | XM_017006203.2 | c.1457C>A | p.Ala486Glu | missense_variant | 15/15 | ||
SLC9A9 | XM_011512703.4 | c.1160C>A | p.Ala387Glu | missense_variant | 13/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC9A9 | ENST00000316549.11 | c.1808C>A | p.Ala603Glu | missense_variant | 16/16 | 1 | NM_173653.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000421 AC: 64AN: 152148Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000501 AC: 126AN: 251438Hom.: 0 AF XY: 0.000486 AC XY: 66AN XY: 135878
GnomAD4 exome AF: 0.000438 AC: 640AN: 1461882Hom.: 1 Cov.: 31 AF XY: 0.000444 AC XY: 323AN XY: 727242
GnomAD4 genome AF: 0.000421 AC: 64AN: 152148Hom.: 0 Cov.: 32 AF XY: 0.000457 AC XY: 34AN XY: 74324
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 11, 2022 | The c.1808C>A (p.A603E) alteration is located in exon 16 (coding exon 16) of the SLC9A9 gene. This alteration results from a C to A substitution at nucleotide position 1808, causing the alanine (A) at amino acid position 603 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2024 | SLC9A9: BP4 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at